Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1966 1
1968 2
1970 2
1971 1
1973 4
1974 2
1975 1
1976 1
1977 1
1979 1
1980 1
1981 2
1982 2
1983 1
1984 1
1985 1
1987 2
1989 2
1990 4
1991 2
1992 4
1993 1
1994 1
1995 4
1996 3
1997 2
1998 3
2001 2
2002 2
2004 1
2007 2
2008 2
2009 1
2011 2
2014 1
2017 1
2018 1
2019 1
2020 1
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

67 results

Results by year

Filters applied: . Clear all
Page 1
Pathophysiology, diagnosis and treatment of ascites in cirrhosis.
Arroyo V. Arroyo V. Ann Hepatol. 2002 Apr-Jun;1(2):72-9. Ann Hepatol. 2002. PMID: 15115971 Free article. Review.
TIPS is more effective in the long term control of ascites but may impair hepatic function and induce chronic hepatic encephalopathy....
TIPS is more effective in the long term control of ascites but may impair hepatic function and induce chronic hepatic encep …
Wernicke encephalopathy and ethanol-related syndromes.
Kim TE, Lee EJ, Young JB, Shin DJ, Kim JH. Kim TE, et al. Semin Ultrasound CT MR. 2014 Apr;35(2):85-96. doi: 10.1053/j.sult.2013.09.004. Semin Ultrasound CT MR. 2014. PMID: 24745886 Review.
This review provides an overview of Wernicke encephalopathy and other ethanol-related brain changes, such as chronic brain atrophy, Marchiafava-Bignami disease, osmotic demyelination syndrome, chronic hepatic encephalopathy, and acute alcohol withdrawal. As …
This review provides an overview of Wernicke encephalopathy and other ethanol-related brain changes, such as chronic brain atrophy, Marchiaf …
Benzodiazepine receptor antagonists for acute and chronic hepatic encephalopathy.
Als-Nielsen B, Kjaergard LL, Gluud C. Als-Nielsen B, et al. Cochrane Database Syst Rev. 2001;(4):CD002798. doi: 10.1002/14651858.CD002798. Cochrane Database Syst Rev. 2001. PMID: 11687160 Updated. Review.
OBJECTIVES: To evaluate the efficacy and safety of benzodiazepine receptor antagonists for patients with acute or chronic hepatic encephalopathy. SEARCH STRATEGY: Eligible trials were identified through The Cochrane Hepato-Biliary Group Controlled Trials Regi …
OBJECTIVES: To evaluate the efficacy and safety of benzodiazepine receptor antagonists for patients with acute or chronic hepatic …
Probiotics for people with hepatic encephalopathy.
Dalal R, McGee RG, Riordan SM, Webster AC. Dalal R, et al. Cochrane Database Syst Rev. 2017 Feb 23;2(2):CD008716. doi: 10.1002/14651858.CD008716.pub3. Cochrane Database Syst Rev. 2017. PMID: 28230908 Free PMC article. Review.
OBJECTIVES: To determine the beneficial and harmful effects of probiotics in any dosage, compared with placebo or no intervention, or with any other treatment for people with any grade of acute or chronic hepatic encephalopathy. This review did not consider t …
OBJECTIVES: To determine the beneficial and harmful effects of probiotics in any dosage, compared with placebo or no intervention, or with a …
Rifaximin versus nonabsorbable disaccharides in the management of hepatic encephalopathy: a meta-analysis.
Jiang Q, Jiang XH, Zheng MH, Jiang LM, Chen YP, Wang L. Jiang Q, et al. Eur J Gastroenterol Hepatol. 2008 Nov;20(11):1064-70. doi: 10.1097/MEG.0b013e328302f470. Eur J Gastroenterol Hepatol. 2008. PMID: 19047837 Review.
RR was 0.98 (95% CI: 0.85-1.13; P=0.74) for acute hepatic encephalopathy in 157 patients and 0.87 (95% CI: 0.40-1.88; P=0.72) for chronic hepatic encephalopathy in 96 patients, respectively. There was no significant difference between rifaximin and nonabsorba …
RR was 0.98 (95% CI: 0.85-1.13; P=0.74) for acute hepatic encephalopathy in 157 patients and 0.87 (95% CI: 0.40-1.88; P=0.72) for chronic …
Probiotics for patients with hepatic encephalopathy.
McGee RG, Bakens A, Wiley K, Riordan SM, Webster AC. McGee RG, et al. Cochrane Database Syst Rev. 2011 Nov 9;(11):CD008716. doi: 10.1002/14651858.CD008716.pub2. Cochrane Database Syst Rev. 2011. PMID: 22071855 Updated. Review.
OBJECTIVES: To quantify the beneficial and harmful effects of any probiotic in any dosage, compared with placebo or no intervention, or with any other treatment for patients with any grade of acute or chronic hepatic encephalopathy as assessed from randomi …
OBJECTIVES: To quantify the beneficial and harmful effects of any probiotic in any dosage, compared with placebo or no intervention, or with …
Oral L-ornithine-L-aspartate therapy of chronic hepatic encephalopathy: results of a placebo-controlled double-blind study.
Stauch S, Kircheis G, Adler G, Beckh K, Ditschuneit H, Görtelmeyer R, Hendricks R, Heuser A, Karoff C, Malfertheiner P, Mayer D, Rösch W, Steffens J. Stauch S, et al. J Hepatol. 1998 May;28(5):856-64. doi: 10.1016/s0168-8278(98)80237-7. J Hepatol. 1998. PMID: 9625322 Clinical Trial.
Therefore, the therapeutic efficacy of oral L-ornithine-L-aspartate, which improves impaired ammonia detoxification, was investigated in patients with cirrhosis, hyperammonemia and stable, overt, chronic hepatic encephalopathy, and in subclinical hepatic ence …
Therefore, the therapeutic efficacy of oral L-ornithine-L-aspartate, which improves impaired ammonia detoxification, was investigated in pat …
67 results